GE, Roche Enter Partnership to Develop Integrated Digital Diagnostics Platform to Improve Oncology and Critical Care Treatment
January 08 2018 - 1:00AM
Business Wire
- Companies aim to develop
jointly-branded clinical decision support software for faster, more
accurate, more confident decision-making, enabling earlier
diagnosis and individualized treatment
- Partnership will apply advanced
analytics to in-vivo data from GE’s medical imaging and monitoring
equipment with in-vitro data from Roche’s biomarker, tissue
pathology, genomics and sequencing portfolio
GE Healthcare has entered into a strategic, long-term
partnership with Roche (SIX: RO, ROG; OTCQX: RHHBY) to jointly
develop and co-market digital clinical decision support solutions.
The partnership will initially focus on products that accelerate
and improve individualized treatment options for cancer and
critical care patients.
This press release features multimedia. View
the full release here:
http://www.businesswire.com/news/home/20180107005109/en/
GE, Roche Enter Partnership to develop an
industry-first digital platform, using advanced analytics to
provide workflow solutions and apps that support clinical decisions
(Photo: Business Wire)
The two companies aim to develop an industry-first digital
platform, using advanced analytics to provide workflow solutions
and apps that support clinical decisions. This will allow the
seamless integration and analysis of in-vivo and in-vitro data,
patient records, medical best practice, real time monitoring and
the latest research outcomes. Clinicians will then have the
comprehensive decision support for providing the right treatment
and quality of care for their patients.
For example, oncology care teams with multiple specialists will
have a comprehensive data dashboard to review, collaborate and
align on treatment decisions for cancer patients at each stage of
their disease. In the critical care setting, data from a patient’s
hospital monitoring equipment will be integrated with their
biomarker, tissue pathology, genomic and sequencing data, helping
physicians to identify, or even predict severe complications before
they strike.
GE Healthcare is a worldwide leader in medical imaging
equipment, while Roche Diagnostics is the global leader in in-vitro
diagnostics.
“This is the first time that two major players in healthcare
have combined advanced analytics with in-vivo and in-vitro
diagnostics to this degree. We believe this alliance will help
accelerate the delivery of data-driven precision health for
customers, patients and the healthcare industry,” said Kieran
Murphy, President & CEO of GE Healthcare.
“This unique partnership will deliver innovative solutions and
insights in clinical decision-making. Our goal is to support
clinicians and other relevant stakeholders for the benefit of
patients by providing the right decision support at the right time
and through comprehensive digital offerings,” said Roland
Diggelmann, CEO Roche Diagnostics.
About GE Healthcare:
Harnessing data and analytics across hardware, software and
biotech, GE Healthcare is the $18 billion healthcare business of GE
(NYSE: GE). As a leading provider of medical imaging equipment,
with a track record of more than 100 years in the industry and more
than 50,000 employees across 100 countries, we transform healthcare
by delivering better outcomes for providers and patients. Visit us
at www.gehealthcare.com or follow us on Facebook, LinkedIn, Twitter
and The Pulse for latest news
About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics
focused on advancing science to improve people’s lives. The
combined strengths of pharmaceuticals and diagnostics under one
roof have made Roche the leader in personalised healthcare – a
strategy that aims to fit the right treatment to each patient in
the best way possible.
The Roche Group, headquartered in Basel, Switzerland, is active
in over 100 countries and in 2016 employed more than 94,000 people
worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and
posted sales of CHF 50.6 billion. Genentech, in the United States,
is a wholly owned member of the Roche Group. Roche is the majority
shareholder in Chugai Pharmaceutical, Japan. For more information,
please visit www.roche.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180107005109/en/
GE HealthcareWilliam Spiers +44
7971276757william.spiers@ge.comorJennifer Fox +1 +1 414 530
3027jennifer.r.fox@ge.comorHannah Huntly +44 7887
824201hannah.huntly@ge.comorRoche Group Media
RelationsPhone: +41 -61 688 8888 / e-mail:
media.relations@roche-global.com- Nicolas Dunant (Head)- Patrick
Barth- Ulrike Engels-Lange- Simone Oeschger- Anja von Treskow
GE Aerospace (NYSE:GE)
Historical Stock Chart
From Aug 2024 to Sep 2024
GE Aerospace (NYSE:GE)
Historical Stock Chart
From Sep 2023 to Sep 2024